TTM Capital was awarded two honors: China's Best Return Venture Capital Institution
At the beginning of the new year, TTM Capital welcomed a "great start." On January 18, the annual list of equity investment by China Bridge was announced, and TTM Capital won two prestigious awards: "China's Best Return Venture Capital Institution" and "China's Most Promising Investment Institution" for 2023.
At the beginning of the new year, TTM Capital welcomed a "great start." On January 18, the annual list of equity investment by China Bridge was announced, and TTM Capital won two prestigious awards: "China's Best Return Venture Capital Institution" and "China's Most Promising Investment Institution" for 2023.
The annual list of equity investment in by China Bridge has been published for 10 consecutive years. The scope of the list covers active institutions in the Chinese private equity market and serves as an important reference for interpreting future trends and investment directions in the industry. This list is also considered one of the most influential rankings in the industry.
TTM Capital will continue to seek new development breakthroughs in 2024. In the future, TTM Capital will focus on deep alliances with ecological partners to face "adversity" together, adhering to the strategy of " Comprehensive linkage, multi-disciplinary sourcing, strategic alliance," promoting the globalization of medical enterprises, and helping companies "go global"; upholding the value orientation and concept of "uniting talents to benefit the world, working hand in hand for mutual success, sailing together to overcome difficulties, and creating miracles," embracing partners to achieve win-win outcomes!
About XinThera Pharmaceuticals, Inc
XinThera was established in 2021, based on a structural drug discovery platform, focusing on fast follow small molecule drug development for First-in-Class and blockbuster drugs. Since receiving seed round financing in February 2021, the company has rapidly developed its business. The company was co-founded by Dr. Qing Dong, former Chief Scientist at Hengrui Pharmaceuticals, and seasoned entrepreneurs who had successfully started four companies in the U.S. and built several NASDAQ-listed companies. The R&D team consists of senior oncology and immunology experts with over twenty years of experience in new drug development, having successfully developed seven marketed drugs and a dozen clinical candidates.
Who we are
TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies. TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.
